China Isotope & Radiation Corp. (1763) AI Stock Analysis

• Market Cap: HK$6.40B
• Dividend Yield: 2.76%
• Average Volume (3M): 508.32K
• Price to Earnings (P/E): 18.2
• Beta (1Y): 0.86
• Revenue Growth: 13.59%
• EPS Growth: 6.31%
• Country: HK
• Employees: 3,367
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): N/A
• Shares Outstanding: 79,968,800
• 10 Day Avg. Volume: 533,840
• 30 Day Avg. Volume: 508,324
• PEG Ratio: 0.85
• Price to Book (P/B): 0.65
• Price to Sales (P/S): 0.43
• P/FCF Ratio: 22.90
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 74 Outperform
• Price Target: HK$26.00 ▲(10.54% Upside)
• Action: Reiterated Date: 01/06/26
• Date: Action: Reiterated 01/06/26

Overall score is driven primarily by strong financial performance (notably revenue growth and improving profitability, plus moderate leverage), supported by bullish technical trend conditions (price above major moving averages and positive MACD). Valuation is reasonable with a modest dividend yield, while cash flow uncertainty limits the upside to the score.

Positive Factors

Revenue Growth

Sustained 14% top-line growth indicates expanding demand for core isotope and radiation products across medical and industrial end markets. Durable revenue expansion supports capacity investments, R&D and contractual partnerships that underpin long-term market share gains and product pipeline development.

Negative Factors

Cash Flow Uncertainty

Missing and potentially volatile cash flow metrics impede assessment of the company’s ability to internally fund maintenance, facility expansions and regulatory compliance. In capital-intensive isotope production, unpredictable cash generation raises execution and liquidity risk over the medium term.

China Isotope & Radiation Corp. Business Overview & Revenue Model

Company Description

China Isotope & Radiation Corporation engages in the research and development, manufacture, and sale of diagnostic and therapeutic radiopharmaceuticals and radioactive source products for medical and industrial applications in China. It operates t...

Read more

China Isotope & Radiation Corporation engages in the research and development, manufacture, and sale of diagnostic and therapeutic radiopharmaceuticals and radioactive source products for medical and industrial applications in China. It operates t...

How the Company Makes Money

The company generates revenue through multiple streams, primarily by selling isotopes used in medical imaging and cancer treatment, which are in high demand within the healthcare sector. Additionally, it earns income from the provision of radiatio...

Read more

The company generates revenue through multiple streams, primarily by selling isotopes used in medical imaging and cancer treatment, which are in high demand within the healthcare sector. Additionally, it earns income from the provision of radiatio...

China Isotope & Radiation Corp. Financial Statement Overview

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	7.62B	7.57B	6.63B	6.15B	5.14B	4.27B
Gross Profit	3.68B	3.68B	3.48B	3.51B	3.24B	2.62B
EBITDA	1.34B	1.28B	1.22B	1.05B	901.43M	717.43M
Net Income	424.14M	406.64M	370.97M	392.27M	335.75M	213.58M
Balance Sheet
Total Assets	15.65B	14.77B	13.19B	11.69B	10.47B	9.19B
Cash, Cash Equivalents and Short-Term Investments	2.69B	2.63B	2.94B	2.93B	2.79B	2.59B
Total Debt	3.02B	2.57B	1.70B	903.86M	856.63M	749.64M
Total Liabilities	7.69B	7.02B	6.05B	5.13B	4.44B	3.68B
Stockholders Equity	5.08B	5.01B	4.69B	4.47B	4.18B	3.89B
Cash Flow
Free Cash Flow	-766.49M	142.48M	-812.66M	328.66M	366.59M	-118.01M
Operating Cash Flow	14.07M	142.48M	84.96M	862.66M	794.31M	291.91M
Investing Cash Flow	-347.00M	-564.81M	-429.88M	-506.62M	-907.36M	-423.90M
Financing Cash Flow	608.94M	499.70M	484.37M	-291.50M	-97.44M	-156.25M

China Isotope & Radiation Corp. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 23.52
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1763, the sentiment is Negative. The current price of 23.52 is above the 20-day moving average (MA) of 20.65, above the 50-day MA of 21.09, and above the 200-day MA of 18.90, indicating a neutral trend. The MACD of -0.23 indicates Positive momentum. The RSI at 43.31 is Neutral, neither overbought nor oversold. The STOCH value of 14.79 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1763.

China Isotope & Radiation Corp. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1763	74 Outperform	HK$6.40B	18.20	8.41%	2.76%	13.59%	6.31%
1789	74 Outperform	HK$7.21B	17.31	11.91%	1.26%	25.18%	55.79%
1858	69 Neutral	HK$7.66B	19.30	9.39%	1.88%	14.56%	61.60%
2190	58 Neutral	HK$8.16B	27.86	4.88%	0.48%	35.01%	483.73%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
2160	43 Neutral	HK$3.69B	-218.71	0.22%	―	-4.38%	―

China Isotope & Radiation Corp. Corporate Events